SU1215710A1 - Method of treatment of tythus-paratyphoid infection and salmonollosis enterocolitis - Google Patents

Method of treatment of tythus-paratyphoid infection and salmonollosis enterocolitis Download PDF

Info

Publication number
SU1215710A1
SU1215710A1 SU792793081A SU2793081A SU1215710A1 SU 1215710 A1 SU1215710 A1 SU 1215710A1 SU 792793081 A SU792793081 A SU 792793081A SU 2793081 A SU2793081 A SU 2793081A SU 1215710 A1 SU1215710 A1 SU 1215710A1
Authority
SU
USSR - Soviet Union
Prior art keywords
days
patients
treatment
blood
infection
Prior art date
Application number
SU792793081A
Other languages
Russian (ru)
Inventor
Камильджон Ахмеджанович Зуфаров
Камал Хаджиевич Хаджиев
Юрий Григорьевич Чирко
Original Assignee
Ташкентский Государственный Ордена Трудового Красного Знамени Медицинский Институт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ташкентский Государственный Ордена Трудового Красного Знамени Медицинский Институт filed Critical Ташкентский Государственный Ордена Трудового Красного Знамени Медицинский Институт
Priority to SU792793081A priority Critical patent/SU1215710A1/en
Application granted granted Critical
Publication of SU1215710A1 publication Critical patent/SU1215710A1/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

Изобретение относитс  к медицине и может быть использовано дл  лечени  тифо-паратифозной инфекции и сальмонеллезных энтероколитов.This invention relates to medicine and can be used to treat typhoid paratyphoid infection and Salmonella enterocolitis.

Цель изобретени  - сокращение срЬ ка лечени .The purpose of the invention is to reduce the average of treatment.

Способ осуществл ют следующим об- разЬм.The method is carried out as follows.

Вольному с подтвержденным диагнозом брюшного тифа вместе с общеукрепл ющей терапией с применением левомицетина (2 г в сутки) дополнительно внутримьппечно ввод т цитохром С в зависимости от т жести протекае- мого заболевани : по 10 мг 1 раз в сутки при средней форме течени  . болезни; по 10 мг 2 раза в сутки - при т желой форме течени . Лечение провод т 10-12 сут. при средней форме и 10-16 сут при т желой форме течени  брюшного тифа.A free patient with a confirmed diagnosis of typhoid fever, together with general strengthening therapy using chloramphenicol (2 g per day), is additionally administered cytochrome C intramuscularly depending on the severity of the disease: 10 mg once a day with an average form of the course. diseases; 10 mg 2 times a day - with a severe form of flow. The treatment is carried out for 10-12 days. with an average form and 10–16 days with a severe form of typhoid fever.

Согласно наблюдени м, благодар  введению цитохрома С в комплексе с общеукрепл ющей терапией и левоми--Редактор Н.Данкулич Заказ 925/5According to observations, due to the introduction of cytochrome C in combination with general strengthening therapy and levomy - Editor N. Dankulich Order 925/5

Составитель А.Модль Техред М.НадьCompiled by A. Modl Tehred M. Nad

Тираж 659 ВНИИПИ Государственного комитета СССРCirculation 659 VNIIPI USSR State Committee

по делам изобретений и открытий t13035, Москва, Ж-35, Раушска  наб., д. 4/5for inventions and discoveries t13035, Moscow, Zh-35, Raushsk nab., 4/5

Филиал ГШП Патент, г. Ужгород, ул. Проектна , 4Branch GShP Patent, Uzhgorod, st. Project, 4

цетином, отрицательные анализы по бактериологическому исследованию крови, мочи и кала при средней форме течени  болезни наблюдаютс  наcetin, negative bacteriological tests of blood, urine and feces in the middle course of the disease are observed on

5-6 сут., при т желой форме - на 15-16 сут.5-6 days., With heavy form - for 15-16 days.

Отмена введени  цитохрома С больным обусловлена отсутствием температуры тела, высевани  сельмонеллыCanceling the introduction of cytochrome C in patients due to the lack of body temperature, seeding of Selmonella

тифа из крови, мочи и кала, содержани  общего белка в сьгооротке крови больных, общим состо нием больных. Согласно предлагаемому способу ка основании наблюдений при среднейtyphoid from blood, urine and feces, total protein content in the blood of patients, the general condition of patients. According to the proposed method, based on observations with an average

форме течени  болезни препарат отмен ют на 10-12 сут., при т желой - на 15-16 сут., в то врем , как при лечении больных известным способом наблюдаетс  снижение температурыin the form of the course of the disease, the drug is withdrawn for 10–12 days, with severe for 15–16 days, while in the treatment of patients in a known manner, a decrease in temperature is observed

тела на 17-18 сут, и общее количество температурных дней составл ет 27,2 сут. Общее пребывание больных в стационаре составл ет 44,2 кой- ко-дней.body for 17-18 days, and the total number of temperature days is 27.2 days. The total hospital stay is 44.2 bed-days.

Корректор Е.Рошко ПодписноеCorrector E.Roshko Subscription

Claims (1)

СПОСОБ ЛЕЧЕНИЯ ТИФО-ПАРАТИФОЗНОЙ ИНФЕКЦИИ И САЛЬМОНЕЛЛЕЗНЫХ ЭНТЕРОКОЛИТОВ путем антибиотикотерапии, отличающийся тем, что, с целью сокращения срока лечения, дополнительно вводят цитохром С.METHOD FOR TREATING TYPHO-PARATYPHOSIS INFECTION AND SALMONELLOSE ENTEROCOLITES by antibiotic therapy, characterized in that, in order to reduce the duration of treatment, Cytochrome C is additionally administered. цетином, отрицательные анализы по бактериологическому исследованию крови, мочи и кала при средней форме течения болезни наблюдаются на 5 5-6 сут., при тяжелой форме - на 15-16 сут.cetin, negative tests for bacteriological examination of blood, urine and feces with an average form of the course of the disease are observed for 5 5-6 days., In severe form - for 15-16 days. Отмена введения цитохрома С больным обусловлена отсутствием температуры тела, высевания сельмонеллы 10 тифа из крови, мочи и кала, содержания общего белка в сыворотке крови больных, общим состоянием больных.The cancellation of the administration of cytochrome C to patients is caused by the absence of body temperature, plating of typhoid 10 typhoid from blood, urine and feces, the total protein content in the blood serum of patients, and the general condition of patients. Согласно предлагаемому способу на основании наблюдений при средней 15 форме течения болезни препарат отменяют на 10-12 сут., при тяжелой на 15-16 сут., в то время, как при лечении больных известным способом наблюдается снижение температуры 20 тела на 17-18 сут. и общее количество температурных дней составляет 27,2 сут. Общее пребывание больных в стационаре составляет 44,2 койко-дней.According to the proposed method, on the basis of observations with an average 15 form of the course of the disease, the drug is canceled for 10-12 days., For severe for 15-16 days., While in the treatment of patients in a known manner, a decrease in body temperature of 20 to 17-18 days . and the total number of temperature days is 27.2 days. The total hospital stay of patients is 44.2 bed days. tt
SU792793081A 1979-05-03 1979-05-03 Method of treatment of tythus-paratyphoid infection and salmonollosis enterocolitis SU1215710A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU792793081A SU1215710A1 (en) 1979-05-03 1979-05-03 Method of treatment of tythus-paratyphoid infection and salmonollosis enterocolitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU792793081A SU1215710A1 (en) 1979-05-03 1979-05-03 Method of treatment of tythus-paratyphoid infection and salmonollosis enterocolitis

Publications (1)

Publication Number Publication Date
SU1215710A1 true SU1215710A1 (en) 1986-03-07

Family

ID=20839288

Family Applications (1)

Application Number Title Priority Date Filing Date
SU792793081A SU1215710A1 (en) 1979-05-03 1979-05-03 Method of treatment of tythus-paratyphoid infection and salmonollosis enterocolitis

Country Status (1)

Country Link
SU (1) SU1215710A1 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Вальдман А.А. Паратифозна инфекци . Л.: Медицина, 1955, с. 7. *

Similar Documents

Publication Publication Date Title
Larson et al. Undescribed toxin in pseudomembranous colitis.
DONALDSON et al. Lupus-erythematosus-like disease in three unrelated women with hereditary angioneurotic edema
Dhar et al. Effects of hematin in hepatic porphyria: further studies
Kamerbeek et al. Prussian blue in therapy of thallotoxicosis: an experimental and clinical investigation
SHAUGHNESSY et al. Experimental human bacillary dysentery: polyvalent dysentery vaccine in its prevention
MAGILL et al. Oxytetracycline-streptomycin therapy in brucellosis due to Brucella melitensis
PRIZONT et al. Jejunal Bacterial Flora in Chronic Small Bowel Disease: I. Celiac Disease. II. Regional Enteritis
SU1215710A1 (en) Method of treatment of tythus-paratyphoid infection and salmonollosis enterocolitis
Jones et al. Treatment of recurrent bacteriuria with pivmecillinam (FL 1039)
Hatoff Perineal Crohn's Disease Complicated by nic Liver Abscess During Metronidazole Therapy
Gillam et al. A case of renal moniliasis
Wirts et al. The correction of postgastrectomy malabsorption following a jejunal interposition operation
BRYAN et al. Small bowel perforation in Fabry's disease
Pesigan et al. Pararosaniline pamoate (CI-403-A) in the treatment of Schistosoma japonicum infection in the Philippines
JACOBS JR et al. Nongonococcal urethritis: the role of Chlamydia trachomatis
MEADE III Treatment of chronic mucocutaneous candidiasis
Chinnery et al. Fulminant encephalopathy due to the catastrophic primary antiphospholipid syndrome.
Ekberg et al. Pharmacokinetic and therapeutic studies of pivmecillinam in patients with normal and impaired renal function
Nishida et al. Therapeutic efficacy of bicyclomycin for shigellosis experimentally induced in rhesus monkeys
Siboulet et al. A New “One-Minute” Treatment of Gonorrhoea
Lannek et al. Toxicity of Halogenated Oxyquinolines in Dogs. A Clinical Study: III. Intoxication Experiments
Fairbrother et al. Treatment of urinary infections with cycloserine
SU1286212A1 (en) Method of treatment of dysbacteriosis of intestine
SU850083A1 (en) "pantogam" medicine for treating urination disorders
MCCARTHY et al. Fatal bone-marrow pulmonary emboli in multiple myeloma